Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective treatment and a median survival time of 2–5 yrs. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success until 2011, when European approva...

Full description

Bibliographic Details
Main Author: V. Cottin
Format: Article
Language:English
Published: European Respiratory Society 2012-06-01
Series:European Respiratory Review
Subjects:
Online Access:http://err.ersjournals.com/content/21/124/161.full.pdf+html
_version_ 1811250647244210176
author V. Cottin
author_facet V. Cottin
author_sort V. Cottin
collection DOAJ
description Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective treatment and a median survival time of 2–5 yrs. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success until 2011, when European approval was given for the first treatment for IPF, pirfenidone. Four key clinical trials supported the efficacy and tolerability of pirfenidone. In recently published results from two phase III randomised, double-blind, placebo-controlled, multinational trials evaluating pirfenidone (studies 004 and 006), patients with mild-to-moderate IPF were screened for eligibility using the following functional criteria: forced vital capacity (FVC) ≥50% predicted; diffusing capacity of the lung for carbon monoxide ≥35%; and 6-min walk test (6MWT) distance ≥150 m. Only study 004 met the primary end-point of change in per cent predicted FVC at week 72 (p<0.001). Pooled analysis of primary end-point data from both studies also showed that pirfenidone significantly reduced the decline in per cent predicted FVC compared to placebo (p<0.005). Evidence of beneficial effects of pirfenidone treatment was also observed with regard to several secondary end-points, including progression-free survival time, categorical FVC change, and mean change from baseline to week 72 in 6MWT distance. Pirfenidone was generally well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. The pooled study results, coupled with recent data regarding the prognostic significance of changes in FVC and 6MWT, provide further evidence of a clinically meaningful treatment benefit with pirfenidone in patients with IPF.
first_indexed 2024-04-12T16:07:47Z
format Article
id doaj.art-2cb04bec4ca8402eb4722c8f412a081d
institution Directory Open Access Journal
issn 0905-9180
1600-0617
language English
last_indexed 2024-04-12T16:07:47Z
publishDate 2012-06-01
publisher European Respiratory Society
record_format Article
series European Respiratory Review
spelling doaj.art-2cb04bec4ca8402eb4722c8f412a081d2022-12-22T03:26:00ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172012-06-0121124161167Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomesV. CottinIdiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective treatment and a median survival time of 2–5 yrs. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success until 2011, when European approval was given for the first treatment for IPF, pirfenidone. Four key clinical trials supported the efficacy and tolerability of pirfenidone. In recently published results from two phase III randomised, double-blind, placebo-controlled, multinational trials evaluating pirfenidone (studies 004 and 006), patients with mild-to-moderate IPF were screened for eligibility using the following functional criteria: forced vital capacity (FVC) ≥50% predicted; diffusing capacity of the lung for carbon monoxide ≥35%; and 6-min walk test (6MWT) distance ≥150 m. Only study 004 met the primary end-point of change in per cent predicted FVC at week 72 (p<0.001). Pooled analysis of primary end-point data from both studies also showed that pirfenidone significantly reduced the decline in per cent predicted FVC compared to placebo (p<0.005). Evidence of beneficial effects of pirfenidone treatment was also observed with regard to several secondary end-points, including progression-free survival time, categorical FVC change, and mean change from baseline to week 72 in 6MWT distance. Pirfenidone was generally well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. The pooled study results, coupled with recent data regarding the prognostic significance of changes in FVC and 6MWT, provide further evidence of a clinically meaningful treatment benefit with pirfenidone in patients with IPF.http://err.ersjournals.com/content/21/124/161.full.pdf+htmlForced vital capacityidiopathic pulmonary fibrosispirfenidone
spellingShingle V. Cottin
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
European Respiratory Review
Forced vital capacity
idiopathic pulmonary fibrosis
pirfenidone
title Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
title_full Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
title_fullStr Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
title_full_unstemmed Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
title_short Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
title_sort changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
topic Forced vital capacity
idiopathic pulmonary fibrosis
pirfenidone
url http://err.ersjournals.com/content/21/124/161.full.pdf+html
work_keys_str_mv AT vcottin changingtheidiopathicpulmonaryfibrosistreatmentapproachandimprovingpatientoutcomes